The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study

Hereditary Cancer in Clinical Practice

LaCreis R Kidd⁴  Kevin S Kimbro⁷  Marshall Tulloch-Reid⁶  Norma McFarlane-Anderson⁵  Maria Jackson²  Rafael E Flores-Obando³  Nayla C Kidd⁴  Camille Ragin¹  Dominique Z Jones⁴ 

[1] Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA;Department of Community Health and Psychiatry, University of West Indies, Mona, Kingston, Jamaica;Molecular and Cellular Biology Program, State University of New York, Brooklyn, NY, USA;Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, USA;Department of Basic Medical Sciences, University of the West Indies, Mona Campus, Kingston, Jamaica;Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston, Jamaica;Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, Durham, NC, USA

关键词: Single nucleotide polymorphisms;    Inflammatory-related sequence variants;    Prostate cancer;   

Others  :  805875
DOI  :  10.1186/1897-4287-11-19

 received in 2013-07-29, accepted in 2013-12-03,  发布年份 2013

【 摘 要 】

Purpose

Although case–control studies have evaluated the role of variant inflammatory-related loci in prostate cancer, their impact is virtually unknown among men of African descent. To address this, we evaluated the impact of inflammatory cytokine single nucleotide polymorphisms (SNPs) on prostate cancer risk for men of African descent.

Methods

Forty-four SNPs in inflammatory cytokine-associated genes were evaluated among 814 African-American and Jamaican men (279 prostate cancer cases and 535 controls) using Illumina’s Golden gate genotyping system. Individual SNP effects were evaluated using logistic regression analysis.

Results

Four SNPs were modestly associated with prostate cancer after adjusting for age. In the total population, inheritance of the IL1R2 rs11886877 AA, IL8RB rs11574752 AA, TNF rs1800629 GA + AA, and TNF rs673 GA genotypes modestly increased prostate cancer risk by 1.45 to 11.7-fold relative to the referent genotype. Among U.S. men, age-adjusted dominant, recessive and additive genetic models for the IL1R2 rs11886877 locus were linked to an increase in prostate cancer susceptibility. However, these main effects did not persist after adjusting for multiple hypothesis testing.

Conclusion

Our preliminary data does not strongly support the hypothesis that inflammatory-related sequence variants influence prostate cancer risk among men of African descent. However, further evaluation is needed to assess whether other variant inflammatory-related genes may contribute to prostate cancer risk and disease progression in larger and ethnically diverse multi-center studies.

【 授权许可】

   
2013 Jones et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420(6917):860-867.
• [2]Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C: Inflammation and prostate cancer. Future Oncol 2008, 4(5):637-645.
• [3]Sfanos KS, De Marzo AM: Prostate cancer and inflammation: the evidence. Histopathology 2012, 60(1):199-215.
• [4]Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ: Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013, 49(4):938-945.
• [5]Feghali CA, Wright TM: Cytokines in acute and chronic inflammation. Front Biosci 1997, 2:d12-d26.
• [6]Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, et al.: Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012, 21(10):1774-1782.
• [7]Berhane N, Sobti RC, Melesse S, Mahdi SA, Kassu A: Significance of Tumor necrosis factor alpha-308 (G/A) gene polymorphism in the development of prostate cancer. Mol Biol Rep 2012, 39(12):11125-11130.
• [8]Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, et al.: Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 2011, 20(9):1928-1936.
• [9]Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, Alvarez JC, Lorente JA, Cozar JM: RNASEL study of genetics of prostate cancer and its relation to clinical staging. Actas Urol Esp 2012, 36(5):306-311.
• [10]Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, et al.: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002, 32(4):581-583.
• [11]Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, Mittal RD: IL-10–1082 G > A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009, 27(3):389-396.
• [12]Tindall EA, Severi G, Hoang HN, Southey MC, English DR, Hopper JL, Giles GG, Hayes VM: Interleukin-6 promoter variants, prostate cancer risk, and survival. Prostate 2012, 72(16):1701-1707.
• [13]Tindall EA, Severi G, Hoang HN, Ma CS, Fernandez P, Southey MC, English DR, Hopper JL, Heyns CF, Tangye SG, et al.: Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis 2010, 31(10):1748-1754.
• [14]American Cancer S: Cancer Facts and Figures 2012. American Cancer Society: Atlanta, Georgia; 2012.
• [15]American Cancer S: Cancer Facts & Figures for African Americans 2011–2012. American Cancer Society: Atlanta; 2011.
• [16]Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC: Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008, 29(3):573-578.
• [17]Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC: Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 2009, 30(8):1358-1362.
• [18]Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, Ragin C, Jackson M, McFarlane-Anderson N, Tulloch-Reid M, et al.: Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case–control study. Hereditary Cancer Clin Prac 2012, 10(1):16. BioMed Central Full Text
• [19]Jackson MD, Walker SP, Simpson-Smith CM, Lindsay CM, Smith G, McFarlane-Anderson N, Bennett FI, Coard KC, Aiken WD, Tulloch T, et al.: Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control 2012, 23(1):23-33.
• [20]Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al.: Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
• [21]McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9(5):356-369.
• [22]Steemers FJ, Gunderson KL: Whole genome genotyping technologies on the Bead Array platform. Biotechnol J 2007, 2(1):41-49.
• [23]Menashe I, Rosenberg PS, Chen BE: PGA: power calculator for case–control genetic association analyses. BMC Genet 2008, 9:36.
• [24]Song N, Han S, Lee KM, Choi JY, Park SK, Jeon S, Lee Y, Ahn HS, Shin HY, Kang HJ, et al.: Genetic variants in interleukin-2 and risk of lymphoma among children in Korea. Asian Pac J Cancer Prev 2012, 13(2):621-623.
• [25]Gonzalez CA, Sala N, Capella G: Genetic susceptibility and gastric cancer risk. Int J Cancer 2002, 100(3):249-260.
• [26]Lin HC, Liu CC, Kang WY, Yu CC, Wu TT, Wang JS, Wu WJ, Huang CH, Wu MT, Huang SP: Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol Int 2009, 83(4):463-470.
• [27]Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, et al.: TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 2011, 6(7):e21650.
• [28]Chang SY, Su PF, Lee TC: Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1alpha pathway. Cytokine 2009, 45(1):32-38.
• [29]Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M: Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004, 100(7):1388-1396.
• [30]King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al.: Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41(5):524-526.